RVLV:NYSERevolve Group, Inc. Analysis
Data as of 2026-04-29 - not real-time
$26.30
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Revolve Group shows a bullish technical backdrop, with the short‑term moving average sitting above the longer‑term average and a MACD that remains in bullish territory. The RSI sits in the mid‑range, suggesting room for upside without immediate overbought pressure, while trading volume has been on an upward trend, reinforcing the bullish bias.
Fundamentally, the company delivers double‑digit revenue growth and solid gross margins, yet its price multiples are high relative to earnings and book value, and a discounted cash‑flow model points to a fair value well below the current market price. Recent insider selling adds a cautionary note, but analyst consensus remains positive, indicating that the stock may be positioned for a short‑term pullback before any longer‑term appreciation materializes.
Fundamentally, the company delivers double‑digit revenue growth and solid gross margins, yet its price multiples are high relative to earnings and book value, and a discounted cash‑flow model points to a fair value well below the current market price. Recent insider selling adds a cautionary note, but analyst consensus remains positive, indicating that the stock may be positioned for a short‑term pullback before any longer‑term appreciation materializes.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish technical indicators with near‑term price pressure
- High valuation relative to fundamentals
- Recent insider share sales
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Sustained revenue growth and healthy margins
- Elevated beta and volatility indicating sensitivity to market swings
- Analyst consensus still supportive
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Strong brand positioning in the millennial/Gen‑Z fashion segment
- Potential for margin expansion and market share gains
- Long‑term upside relative to discounted cash‑flow valuation
Key Metrics & Analysis
Financial Health
Revenue Growth10.40%
Profit Margin5.04%
P/E Ratio30.6
ROE12.87%
ROA6.87%
Debt/Equity6.33
P/B Ratio3.1
Op. Cash Flow$59.4M
Free Cash Flow$37.4M
Technical Analysis
TrendBullish
RSI56.9
Support$21.43
Resistance$28.42
MA 20$25.25
MA 50$24.39
MA 200$24.28
MACDBullish
VolumeIncreasing
Fear & Greed Index89.59
Valuation
Fair Value$14.54
Target Price$31.21
Upside/Downside18.69%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta1.83
Volatility43.42%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.